← Leaderboards
Holly Ann Sutterlin
Prokaryotics, Inc.
$374,000
Attributed
$374,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $204K · FY2022–23$250K$187.5K$125K$62.5K$0
'22
'23
Funding mix
By agency
NIH$374,000 · 1
By mechanism
R21$374,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Combined Modality Therapy”
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Robert C Alexander · Banner Health$5,101,602
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Xu Chen · University Of California, San Francisco$3,581,285
- Stuart Marcus · Sonalasense Inc$3,491,029
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$3,437,655
Research focus
Combined Modality TherapyAcinetobacter BaumanniiAnalogCombined AntibioticsAntibioticsAmericanBacteremiaBactericideActive SitesBindingBinding ProteinsBiochemicalBiogenesisCarbapenem ResistanceCarbapenem-Resistant EnterobacteriaceaeCell DeathCell EnvelopeCellsAnti-Bacterial AgentsChemosensitizationClinically RelevantCoculture TechniquesCollaborationsCommunities